AVJ16
AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA binding protein IGF2BP1 with a good affinity of Kd of 1.4μM. AVJ16 interferes with IGF2BP1 binding target mRNA to regulate gene expression and translation[1].
Product Specifications
CAS Number
2775241-92-2
UNSPSC
12352005
Target
Apoptosis; Insulin Receptor
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/avj16.html
Concentration
10mM
Purity
99.60
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(N1CCN(CC1)C2=CC3=C(OCO3)C=C2)C4=CC=C(C=C4)CN5C(CO)=CC6=C5C=CC=C6
Molecular Formula
C28H27N3O4
Molecular Weight
469.53
References & Citations
[1]Singh A, et al. Development of a Novel IGF2BP1 Inhibitor as Metastasis-Specific Therapeutic Agent[J]. European Journal of Cancer, 2022, 174: S104-S105.|[2]Wallis N, et al. AVJ16 inhibits the RNA binding protein IGF2BP1 in lung adenocarcinomas and prevents tumor growth in mice[J]. bioRxiv, 2024: 2024.08. 15.608038.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog